Biller LH, Syngal S, Yurgelun MB (2021) Letter to the editor-recent advances in Lynch syndrome: response to Moller et al. Fam Cancer 20(2):121–122. https://doi.org/10.1007/s10689-020-00199-w

Article  PubMed  Google Scholar 

Wang Q, Lasset C, Desseigne F et al (1999) Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res 59(2):294–297

CAS  PubMed  Google Scholar 

Ricciardone MD, Ozcelik T, Cevher B et al (1999) Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 59(2):290–293

CAS  PubMed  Google Scholar 

Hamilton SR, Liu B, Parsons RE et al (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332(13):839–847. https://doi.org/10.1056/NEJM199503303321302

Article  CAS  PubMed  Google Scholar 

Vasen HFA, Suerink M, van Kouwen M (2026) (in press) Constitutioneel mismatch repair deficiëntie-syndroom. In: Klinische Genetica in de Oncologie: Een multidiciplinaire benadering (Red: F.Menko, K.Monkhorst), Boomuitgevers

Suerink M, Ripperger T, Messiaen L et al (2019) Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. J Med Genet 56(2):53–62. https://doi.org/10.1136/jmedgenet-2018-105664

Article  PubMed  Google Scholar 

Amayiri N, Tabori U, Campbell B et al (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138(2):380–385. https://doi.org/10.1002/ijc.29724

Article  CAS  PubMed  Google Scholar 

Mushtaq N, Minhas K, Bashir F et al (2025) Frequency and impact of constitutional mismatch repair deficiency in patients with high-grade glioma, a retrospective analysis of 7 years in Pakistan: an IRRDC study. JCO Glob Oncol 11:e2400247. https://doi.org/10.1200/GO-24-00247

Article  PubMed  Google Scholar 

Bhardwaj S, Singh J, Singh S et al (2025) Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling. J Neurooncol 176(1):16. https://doi.org/10.1007/s11060-025-05261-0

Article  CAS  PubMed  Google Scholar 

Ercan AB, Aronson M, Fernandez NR et al (2024) Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an international replication repair deficiency consortium cohort study. Lancet Oncol 25(5):668–682 DOI 10.1016/S1470-2045(24)00026 – 3

Article  CAS  PubMed  Google Scholar 

Durno C, Ercan AB, Bianchi V et al (2021) Survival benefit for individuals with constitutional mismatch repair deficiency undergoing surveillance. J Clin Oncol 39(25):2779–2790. https://doi.org/10.1200/JCO.20.02636

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durno CA, Aronson M, Tabori U, Malkin D, Gallinger S, Chan HS (2012) Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59(4):652–656. https://doi.org/10.1002/pbc.24019

Article  PubMed  Google Scholar 

Das A, MacFarland SP, Meade J et al (2024) Clinical updates and surveillance recommendations for DNA replication repair deficiency syndromes in children and young adults. Clin Cancer Res 30(16):3378–3387.

Article  CAS  PubMed  Google Scholar 

Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34(19):2206–2211. https://doi.org/10.1200/JCO.2016.66.6552

Article  CAS  PubMed  Google Scholar 

Das A, Sudhaman S, Morgenstern D et al (2022) Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med 28(1):125–135. https://doi.org/10.1038/s41591-021-01581-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das A, Tabori U, Sambira Nahum LC et al (2023) Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency. Clin Cancer Res 29(23):4770–4783.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das A, Fernandez NR, Levine A et al (2024) Combined immunotherapy improves outcome for replication-repair-deficient (RRD) high-grade glioma failing Anti-PD-1 monotherapy: a report from the international RRD consortium. Cancer Discov 14(2):258–273. https://doi.org/10.1158/2159-8290.CD-23-0559

Article  PubMed  PubMed Central  Google Scholar 

Wimmer K, Kratz CP, Vasen HF et al (2014) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet 51(6):355–365. https://doi.org/10.1136/jmedgenet-2014-102284

Article  CAS  PubMed  Google Scholar 

Vasen HF, Ghorbanoghli Z, Bourdeaut F et al (2014) Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium Care for CMMR-D (C4CMMR-D). J Med Genet 51(5):283–293. https://doi.org/10.1136/jmedgenet-2013-102238

Article  CAS  PubMed  Google Scholar 

Durno C, Boland CR, Cohen S et al (2017) Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 152(6):1605–1614. https://doi.org/10.1053/j.gastro.2017.02.011

Article  PubMed  Google Scholar 

Tabori U, Hansford JR, Achatz MI et al (2017) Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23(11):e32–e7.

Article  PubMed  Google Scholar 

Aronson M, Colas C, Shuen A et al (2022) Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J Med Genet 59(4):318–327.

Article  CAS  PubMed  Google Scholar 

Colas C, Guerrini-Rousseau L, Suerink M et al (2024) ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management. Eur J Hum Genet 32(12):1526–1541. https://doi.org/10.1038/s41431-024-01708-6

Article  PubMed  PubMed Central  Google Scholar 

Guerrini-Rousseau L, Varlet P, Colas C et al (2019) Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv 1(1):vdz033. https://doi.org/10.1093/noajnl/vdz033

Article  PubMed  PubMed Central  Google Scholar 

Fernandez NR, Chang Y, Nunes NM et al (2026) Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma. Nat Genet 58(1):132–142. https://doi.org/10.1038/s41588-025-02420-x

Article  CAS  PubMed  Google Scholar 

Briggs M, Das A, Firth H et al (2023) Recurrent posterior fossa group A (PFA) ependymoma in a young child with constitutional mismatch repair deficiency (CMMRD). Neuropathol Appl Neurobiol 49(1):e12862. https://doi.org/10.1111/nan.12862

Article  PubMed  Google Scholar 

Das AFN, Levine A et al (2023) Trans-species analysis of replication-repair deficient (RRD) medulloblastoma and response to immune-checkpoint inhibition: an IRRDC. Rep Neuro-Oncology 25:i64

Article  Google Scholar 

Rigaud C, Forster VJ, Al-Tarrah H et al (2024) Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort. Pediatr Blood Cancer 71(12):e31302. https://doi.org/10.1002/pbc.31302

Article  PubMed  Google Scholar 

Oshrine BGN, Moore C, Nguyen J et al (2019) B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency. Blood Adv 3(12):1795–1798

Article  PubMed  PubMed Central  Google Scholar 

Wimmer K, Rosenbaum T, Messiaen L (2017) Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91(4):507–519. https://doi.org/10.1111/cge.12904

Article  CAS  PubMed  Google Scholar 

Guerrini-R